Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus VANCERIL DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus VANCERIL DOUBLE STRENGTH.
AZMACORT vs VANCERIL DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, adhesion molecule expression, and eosinophil survival, thereby reducing airway inflammation.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
2 inhalations (168 mcg beclomethasone dipropionate) twice daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life: 1.5–2 hours for beclomethasone dipropionate; 2.7 hours for active metabolite beclomethasone-17-monopropionate. Clinical context: supports twice-daily dosing.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Primarily hepatic metabolism; metabolites excreted renally (~90% as free and conjugated metabolites) and fecally (<10%).
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid